Biognosys participates in a European project with a budget of 11 million euros

Cancer screening and new therapies have significantly decreased the mortality rate of cancer in recent years, despite the higher incidence in the ageing European population. However, cancer’s great molecular complexity and heterogeneity still presents a challenge for developing effective new treatments. Recent technological developments have enabled the generation of molecular datasets that are exponentially increasing our knowledge of cancer. New solutions are now needed to exploit this wealth of data and to understand the cross-talk between pathways as well as the underlying molecular basis of cancer development and progression.

The European Research Consortium CanPathPro will take a unique approach to bring together classic cancer research with omics data and systems biology tools. The CanPathPro-generated platform will enable in silico identification of cancer signaling networks critical for tumor development and will allow users to predict the activation status of individual pathways, following integration of selected data sets in the pathway models. The platform will be of great help in basic cancer research, better treatment and stratification of patients, and more efficient targeted drug development.

Biognosys will perform quantitative analysis of the phospho- and non-phosphoproteome in tumor samples with its cutting edge Hyper Reaction Monitoring technology (HRM-MS) that is especially suited for discovery and quantitative biology applications.  HRM-MS is a next-generation proteomics technology developed by Biognosys that enables reproducible and accurate quantification of up to 8,000 proteins in a single sample.

(Press release)

Image: CanPathPro